Stock comparison
Bioventus
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BVS
Bioventus
Market cap
$628.7M
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BVS | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 36D | 79B | HALO |
| Benjamin Graham | 52D | 83A | HALO |
| Philip Fisher | 41D | 65B | HALO |
| Peter Lynch | 29F | 53D | HALO |
| Joel Greenblatt | 26F | 40D | HALO |
| Charlie Munger | 38D | 80C | HALO |
| Terry Smith | 34F | 84A | HALO |
Side-by-side metrics
| Metric | BVS | HALO |
|---|---|---|
| Market cap | $628.7M | $8.1B |
| P/E (TTM) | 25.0x | 24.0x |
| EV/EBIT | 12.0x | 10.2x |
| ROIC (TTM) | 11.77% | 23.65% |
| Gross margin | 67.78% | 81.24% |
| Net margin | 4.94% | 23.13% |
| Revenue CAGR 5y | 7.15% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.1x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BVS leads on
- Debt / Equity0.1xvs 1.0x+90%
HALO leads on
- Market cap$8.1Bvs $628.7M+92%
- Net margin23.13%vs 4.94%+79%
- Revenue CAGR 5y33.23%vs 7.15%+78%
- ROIC (TTM)23.65%vs 11.77%+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.